Norbaeocystin - PsyBio Therapeutics
Alternative Names: Norbaeocystin-PsyBio TherapeuticsLatest Information Update: 28 Apr 2025
At a glance
- Originator PsyBio Therapeutics
- Developer PsyBio Therapeutics; University of Miami
- Class Neuropsychotherapeutics; Small molecules; Tryptamines
- Mechanism of Action Serotonin receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mental disorders
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Mental-disorders in USA
- 06 Dec 2022 PsyBio Therapeutics files four U.S. Patent Cooperation Treaty (PCT) patent applications related to advancements concerning production methodology, host strains and processes of production
- 23 Sep 2021 PsyBio Therapeutics submits pre-Investigational New Drug application meeting request to the United States Food and Drug Administration